ReviewFrontiers in pharmacology2026
Enhancing secondary metabolite accumulation in medicinal plants to improve immunomodulatory activity.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite progress in enhancing secondary metabolite accumulation to support plant growth and stress tolerance, relatively few studies have established direct links between these increases and enhanced immunoregulatory outcomes in humans. Bridging this gap is essential for advancing pharmacological applications and the development of effective plant-based immune therapeutics. Unlike previous reviews that primarily focus on metabolite enhancement strategies in isolation, this review proposes an integrative translational framework linking plant metabolic reprogramming, metabolite bioavailability, and downstream human immunomodulatory relevance. This review evaluates genetic, biochemical, and ecological strategies used to enhance secondary metabolite accumulation in medicinal plants and assesses their potential to translate into immunomodulatory effects. The available evidence indicates that while elicitor- and biostimulant-based approaches consistently enhance metabolite accumulation, their translation into clinically relevant outcomes is constrained by factors such as bioavailability, metabolic stability, and dose-dependent effects. The review further highlights key limitations and knowledge gaps, emphasising the need for integrative and translational research frameworks to link plant metabolic enhancement with human immune outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.